Can memantine prevent memory impairment induced by MDMA in humans.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON29601

Enrollment

Registered

2011-02-24

Start date

2011-04-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MDMA incuded memory impairment

Interventions

1. Placebo - Placebo

2. Memantine 20 mg - Placebo

3. Placebo - MDMA 75 mg

4. Memantine 20 mg - MDMA 75 mg.

Eligibility

Inclusion criteria

Inclusion criteria: 1. Recreational MDMA users; 2. Age between 18 and 40 years; 3. Free from psychotropic medication; 4. Good physical health; 5. Absence of any major medical, endocrine and neurological condition; 6. Normal weight; 7. Written Informed Consent.

Exclusion criteria

Exclusion criteria: 1. History of drug abuse (other than the use of MDMA) or addiction; 2. Pregnancy or lactation; 3. Excessive drinking; 4. Hypertension; 5. Current or history of psychiatric disorder.

Design outcomes

Primary

Measure	Time frame
Memory performance is the primary outcome and is measured immediately after each cannabis/placebo treatment. Memory is measured with a verbal memory test and a prospecitve memory test.	—

Secondary

Measure	Time frame
Event related potentials are measured while performing the verbal memory tast. P300 will be the outcome measure of the Event related potentials. Measurable and perceptual differences in speech will be studied between MDMA-influenced and non-intoxicated speech.	—

Contacts

Public ContactE.L. Theunissen

e.theunissen@maastrichtuniversity.nl

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)